← Human Trials & Peer-Reviewed Studies
Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial
Plain-language guide to PMID 40892617 (2025): randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 40892617
- Journal
- Journal of the American College of Cardiology
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Verma S et al. (10 authors)
- DOI
- 10.1016/j.jacc.2025.08.046
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide in this randomized controlled trial publication.
Peripheral artery disease (PAD) is prevalent in women and men with type 2 diabetes (T2D).
Sex-based differences exist in its epidemiology, clinical presentation, functional impact, outcomes, and potentially in responses to treatments.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized study.
The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.
The primary endpoint in STRIDE was the ratio to baseline in maximum walking distance (MWD) at week 52 on a constant load treadmill.
Confirmatory secondary endpoints included change in MWD at week 57, change in pain-free walking distance at week 52, and change in PAD-specific Vascular Quality of Life Questionnaire-6 total score from baseline to week 52.
Herein, the researchers report the outcomes analyzed by sex.
What Was Measured
Sex-based differences exist in its epidemiology, clinical presentation, functional impact, outcomes, and potentially in responses to treatments.
Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Peripheral Arterial Disease, Quality of Life, Sex Factors and Walking.
The authors tagged it with the keywords STRIDE, glucagon-like peptide-1 receptor agonist, peripheral artery disease, semaglutide, sex-based differences and type 2 diabetes.
What This Means in Plain Language
The paper is a randomized study of Semaglutide.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (Journal of the American College of Cardiology), a journal based in United States.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.